Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Launched by CHARLES DREW UNIVERSITY OF MEDICINE AND SCIENCE · Sep 24, 2024
Trial Information
Current as of July 06, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Signed and dated informed consent form and HIPPA (Health Insurance Portability and Accountability Act) authorization.
- • Stated willingness to comply with all study procedures and availability for the duration of the study.
- • Male patients 18 years or older
- • Diagnosed with metastatic prostate cancer
- • History of confirmed progressive disease with concurrent use of medical castration (e.g. luteinizing hormone-releasing hormone analogue), or surgical castration
- • Confirmed progressive disease with concurrent use of enzalutamide, apalutamide, darolutamide, and/or abiraterone acetate
- • Clinical decision to start doc infusion with prednisone treatment
- • Adequate bone marrow function (absolute neutrophil count (ANC) more than1500 cells/mm³, platelet count more than 100,000 cells/mm³)
- • Adequate liver function (total bilirubin less than upper limit of normal (ULN), alanine aminotransferase (ALT) less than 1.5 x ULN, aspartate aminotransferase (AST) less than 1.5 x ULN)
- • Adequate renal function (serum creatinine level within normal limits)
- • At least a 6-month or greater life expectancy
- • Willing to stop consuming tea or tea-containing products and quercetin supplements throughout the entire intervention period except for the green tea extract and quercetin provided during study intervention
- Exclusion Criteria:
- • Prior treatment of chemotherapy and/or radiotherapy for metastatic disease
- • Any comorbid condition that would preclude the administration of docetaxel/prednisone
- • Ongoing alcohol abuse
- • Significant medical or psychiatric conditions that would make the patient a poor protocol candidate
- • Prior allergic reaction to tea, tea products or quercetin supplements
- • Allergies to multiple food items or nutritional supplements
About Charles Drew University Of Medicine And Science
Charles Drew University of Medicine and Science (CDU) is a renowned institution dedicated to addressing health disparities and advancing medical research, particularly in underserved communities. As a leader in medical education, CDU emphasizes the importance of culturally competent care and community engagement in its clinical trials. The university fosters innovative research initiatives aimed at improving health outcomes through rigorous scientific inquiry and collaboration with local and global partners. CDU is committed to enhancing healthcare delivery and promoting equity in health through its diverse clinical trial portfolio.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
Piwen Wang, PhD
Principal Investigator
Charles Drew University of Medicine and Science
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported